List of Excipients in Branded Drug TOLCAPONE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Oceanside Pharmaceuticals	TOLCAPONE	tolcapone	68682-938	ANHYDROUS DIBASIC CALCIUM PHOSPHATE
Oceanside Pharmaceuticals	TOLCAPONE	tolcapone	68682-938	CELLULOSE, MICROCRYSTALLINE
Oceanside Pharmaceuticals	TOLCAPONE	tolcapone	68682-938	ETHYLCELLULOSE
Oceanside Pharmaceuticals	TOLCAPONE	tolcapone	68682-938	FERRIC OXIDE RED
Oceanside Pharmaceuticals	TOLCAPONE	tolcapone	68682-938	FERRIC OXIDE YELLOW
Oceanside Pharmaceuticals	TOLCAPONE	tolcapone	68682-938	HYPROMELLOSE

Generic Drugs Containing TOLCAPONE

Company	Ingredient	NDC	Excipient
Par Pharmaceutical Inc	tolcapone	49884-254	CALCIUM PHOSPHATE, DIBASIC, ANHYDROUS
Par Pharmaceutical Inc	tolcapone	49884-254	CELLULOSE, MICROCRYSTALLINE
Par Pharmaceutical Inc	tolcapone	49884-254	FERRIC OXIDE RED
Par Pharmaceutical Inc	tolcapone	49884-254	FERRIC OXIDE YELLOW
Par Pharmaceutical Inc	tolcapone	49884-254	LACTOSE MONOHYDRATE
Par Pharmaceutical Inc	tolcapone	49884-254	MAGNESIUM STEARATE

What are the Most Frequently-Used Excipients in TOLCAPONE?

# Of NDCs	Excipient
1	ANHYDROUS DIBASIC CALCIUM PHOSPHATE
1	CALCIUM PHOSPHATE, DIBASIC, ANHYDROUS
2	CELLULOSE, MICROCRYSTALLINE
1	ETHYLCELLULOSE
1	FERRIC OXIDE RED
2	FERRIC OXIDE YELLOW

Excipient Strategy and Commercial Opportunities for Tolcapone

Last updated: February 28, 2026

What is Tolcapone?

Tolcapone is a catechol-O-methyltransferase (COMT) inhibitor used alongside levodopa/carbidopa in Parkinson’s disease management. Approved in the U.S. in 1998, its clinical profile is marked by efficacy in reducing "on-off" phenomena [1]. The drug’s therapeutic window is narrow due to potential hepatotoxicity, leading to cautious prescribing.

Excipient Strategy for Tolcapone

Key considerations

The formulation of Tolcapone must prioritize stability, bioavailability, and safety. Excipient selection affects shelf life, bioequivalence, and patient compliance.

Critical excipients

• Fillers: Microcrystalline cellulose enhances tablet integrity. Lactose monohydrate provides bulk but can cause issues in lactose-intolerant patients.
• Binders: Hydroxypropyl methylcellulose (HPMC) stabilizes tablet matrix and controls dissolution rate.
• Disintegrants: Croscarmellose sodium ensures rapid tablet breakup, improving absorption.
• Lubricants: Magnesium stearate reduces friction during manufacturing.
• Coatings: Film coatings often contain hydroxypropyl methylcellulose or polyvinyl alcohol to mask taste and protect against moisture.

Formulation challenges

High water affinity of Tolcapone necessitates protection from moisture. Excipient hygroscopicity must be managed, often via desiccants or moisture-impermeable coatings.

Manufacturing Considerations

• Solubility: Tolcapone’s solubility (~3 mg/mL at room temperature) influences excipient choice, favoring disintegrants that promote rapid dissolution.
• Stability: Oxidation-sensitive, requiring antioxidants like ascorbyl palmitate in formulations.
• Compatibility: Excipient interactions must not compromise Tolcapone’s chemical stability or bioavailability.

Commercial Opportunities

Market Dynamics

• The Parkinson’s drug market exceeds USD 8 billion globally, with COMT inhibitors accounting for a modest but growing segment [2].
• Tolcapone’s restrictions limit market penetration compared to entacapone, which has a better safety profile.

Development Opportunities

• Extended-release formulations: Improved tolerability and adherence.
• Novel excipients: Use of layered or polymer-based excipients enhances stability and taste masking.
• Combination products: Fixed-dose combinations with levodopa/carbidopa for convenience.

Regulatory Incentives

• Patents for formulation innovations, such as moisture-resistant coatings or novel disintegrants, can extend market exclusivity.
• Focus on safety improvements can support branding and labeling claims.

Competitive Landscape

• Tolcapone faces competition mainly from entacapone (Comtan) and opicapone (Ongentys).
• Innovation in excipient strategies offers differentiation, particularly in improving safety and bioavailability.

Summary

Effective excipient strategies for Tolcapone focus on moisture protection, rapid disintegration, and stability enhancement. These solutions can unlock new formulation variants and markets, especially through sustained-release and combination therapies, aligning with emerging Parkinson’s disease treatment trends.

Key Takeaways

• Excipient selection for Tolcapone hinges on stability, moisture control, and dissolution properties.
• Formulation innovations can extend product shelf life and improve safety profiles.
• Market opportunities exist in novel release systems, fixed-dose combinations, and formulations with enhanced stability.
• Regulatory pathways favor patents on novel excipients or delivery systems.
• Competition from existing COMT inhibitors is significant; innovation should focus on safety and convenience.

FAQs

Q1: Why is moisture control critical in Tolcapone formulations?
A1: Tolcapone’s hygroscopic nature makes it prone to stability loss and degradation when exposed to moisture, necessitating moisture-impermeable packaging and desiccants.

Q2: Are there alternative excipients to lactose monohydrate for Tolcapone?
A2: Yes. Microcrystalline cellulose or co-processed materials like crospovidone can be used to avoid lactose-related intolerance issues.

Q3: What excipient innovations can improve Tolcapone’s bioavailability?
A3: Use of superdisintegrants, permeability enhancers, or bioadhesive polymers can improve dissolution and absorption.

Q4: How can Tolcapone formulations reduce hepatotoxicity risks?
A4: Stabilizing formulations with antioxidants and moisture barriers minimize degradation products that could exacerbate toxicity.

Q5: What are the regulatory considerations for excipient modifications in Tolcapone?
A5: Changes must demonstrate equivalence, stability, and bioavailability, often requiring comparability studies and approval through abbreviated new drug applications (ANDAs).

References

[1] Xu, R., et al. (1998). "Pharmacokinetics and Safety of Tolcapone in Parkinson’s Disease." Journal of Clinical Pharmacology, 38(1), 79-86.
[2] Global Market Insights. (2022). "Parkinson’s Disease Drugs Market Report."